Official Title
Expanded Access Program (EAP) for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis (SOD1-ALS)
Brief Summary

The objective is to provide access to tofersen to participants with SOD1-ALS with the most rapidly progressive disease.

Available
Individual Patients
Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Drug: Tofersen
Administered as intrathecal bolus injection
Other Name: BIIB067

Eligibility Criteria

Key Inclusion Criteria: - Medically able to undergo the program procedures, as determined by the treating healthcare professional (HCP). - Weakness attributable to ALS and associated with a mutation in the SOD1 gene (SOD1-ALS). - Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) decline faster than 2.0 points per month (points/month) at most recent assessment, with slope calculated as: [(48) - (ALSFRS-R score at entry)] / [months since symptom onset].

Key Exclusion Criteria: - Previous or current participation in a clinical trial of tofersen. - Use of an investigational medicinal product (IMP) for amyotrophic lateral sclerosis (ALS) within 5 half-lives of the IMP before the first dose of tofersen. - Participant's primary place of residence is outside of the country of treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Contacts

US Biogen Clinical Trial Center
866-633-4636
clinicaltrials@biogen.com

Global Biogen Clinical Trial Center
clinicaltrials@biogen.com

Medical Director
Study Director
Biogen

NCT Number
MeSH Terms
Motor Neuron Disease
Sclerosis
Intervention Name
Tofersen